Central Laboratory Services | Non-Clinical | Clinical Phase I-IV | Preclinical | Early Development | Business Development | Inside Sales
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.
Could biomarkers be the key to unlocking the future of drug discovery? Our EVP and Head of R&D,?Alexandra Snyder, MD, delves into the potential for biomarkers to help the field understand resistance to immunotherapy in her latest publication for the Journal for ImmunoTherapy of Cancer. The article examines the current state of PD-(L)1 therapies and highlights how innovations in biomarker strategies can help understand resistance to checkpoint blockade therapies, with the hope of identifying approaches to deliver more effective treatments to those most in need. Explore how these advancements are set to revolutionize patient care. Read the full article here: https://lnkd.in/e4zsfh4H #PatientFirst | #UnapologeticallyScientific?
We are thrilled to announce that the National Medical Products Administration (NMPA) has approved our Investigational New Drug (IND) application for a novel USP1 inhibitor. This breakthrough therapy targets advanced solid tumors, showcasing our commitment to advancing oncology treatments. This milestone highlights our dedication to developing innovative therapies that address unmet medical needs in cancer treatment. Learn more about this significant step in our journey: https://ow.ly/UvxT50UIbY1 #OncologyInnovation #CancerResearch #INDApproval #USP1Inhibitor #HealthcareAdvances
Scientist with expertise in Cancer Research and Biochemistry, sales executive, key account Management
We are excited to invite you to our upcoming webinar: “Antibody?Drug?Conjugates: A Novel Targeted Approach to Cancer Therapy”. The use of ADC's in clinical trials and approved treatments continues to rise at an ever-increasing pace. Hear from industry experts around the successes, advancements, and future direction of ADCs with a focus on precision oncology. https://lnkd.in/dg7bGhy2
Discover the transformative potential of antibody-drug conjugates (ADCs) in targeted cancer therapy. Our latest presentation dives deep into the journey of ADC development, from Paul Ehrlich's early concept of "magic bullets" to their current status as a leading treatment modality. Learn about the intricate bioanalytical challenges, cutting-edge techniques, and regulatory milestones shaping the future of ADCs in oncology. #CancerResearch #ADCs #Bioanalysis #PrecisionMedicine #WuXiAppTec https://hubs.li/Q02zVC290
Atossa Therapeutics, Inc. to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium #SABCS24 #BreastCancer #ClinicalTrials $ATOS https://lnkd.in/emu_2ZhM
Celebrating CARBOGEN AMCIS colleague Luca Mannocci! It's great to see our scientists' talents highlighted in industry trade publications! Learn more about our ADC and bioconjugation expertise by starting the conversation today! How can we help bring your science to life? #ADCs #bioconjugation #CDMO #bringingyoursciencetolife
?? Exciting to see the latest ADC Contract Manufacturing Market Report by PharmaSource highlighting the growth potential of Antibody-Drug Conjugates (ADCs). Proud to see CARBOGEN AMCIS featured as an important player in this dynamic sector, with valuable insights from one of our own scientists Luca Mannocci. ADCs are truly shaping the future of cancer therapy! ?? Check out the report for more details: https://lnkd.in/gY4cEK8y #ADC #CDMO #PharmaInnovation #CancerTherapy PharmaSource
Unlocking the Future of Medicine: Understanding Clinical Trials Exciting news in oncology! Breakthrough therapies like CAR-T cell treatments and PARP inhibitors are making waves in clinical trials, showing significant promise in battling tough cancers. These therapies are designed to target cancer cells more precisely, improving outcomes and quality of life for patients. Discover how these innovations are changing the game. ??? #CancerResearch #BreakthroughTherapies #HealthInnovation
